Abstract
BCR/ABL tyrosine kinase generated from the chromosomal translocation t(9;22) causes chronic myelogenous leukemia and acute lymphoblastic leukemia. To examine the roles of BCR/ABL-activated individual signaling molecules and their cooperation in leukemogenesis, we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells. The inducibly expressed DN Ras (N17), STAT5 (694F), and DN phosphatidylinositol 3-kinase (Delta p85) inhibited the growth by 90, 55, and 40%, respectively. During the growth inhibition, the expression of cyclin D2 and cyclin D3 was suppressed by N17, 694F, or Delta p85; that of cyclin E by N17; and that of cyclin A by Delta p85. In addition, N17 induced apoptosis in a small proportion of K562, whereas 694F and Delta p85 were hardly effective. In contrast, coexpression of two DN mutants in any combinations induced severe apoptosis. During these cultures, the expression of Bcl-2 was suppressed by N17, 694F, or Delta p85, and that of Bcl-XL by N17. Furthermore, although K562 was resistant to interferon-alpha- and dexamethasone-induced apoptosis, disruption of one pathway by N17, 694F, or Delta p85 sensitized K562 to these reagents. These results suggested that cooperation among these molecules is required for full leukemogenic activities of BCR/ABL.
Highlights
Chronic myelogenous leukemia (CML)1 is a malignant clonal disorder of hematopoietic stem/progenitor cells
Our experiments demonstrated that Ras, STAT5, and phosphatidylinositol 3-kinase (PI3-K) individually participate in breakpoint cluster region (BCR)/ABL-dependent growth and survival of K562, whereas Ras seemed to play a central role among these molecules
To clarify the roles of each signaling molecule in BCR/ABL-mediated cell growth and survival, we inducibly expressed a dominant negative (DN) form of Ras (N17), STAT5 (694F), and PI3-K (⌬p85) by using a Lac-inducible system, in which expression of the target protein was induced by IPTG treatment; each transfected clone was designated as K562/N17, K562/694F, and K562/⌬p85, respectively
Summary
Chronic myelogenous leukemia (CML)1 is a malignant clonal disorder of hematopoietic stem/progenitor cells (as reviewed in Refs. 1–3). To examine the roles of BCR/ABL-activated individual signaling molecules and their cooperation in leukemogenesis, we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.